Novo Nordisk study shows benefits of Victoza

Novo Nordisk has announced new data from a real-world study of the diabetes drug Victoza, which shows the benefits it can offer compared to alternative therapies.

The retrospective study – which utilised real-world data from the IMS data warehouse – showed that Victoza delivered significantly greater improvements in blood glucose control than two commonly used type 2 diabetes therapies.

It also found that a significantly greater percentage of people with type 2 diabetes taking Victoza achieved the American Diabetes Association-recommended blood sugar level target that those receiving the other two drugs.

Victoza was launched in 2009 and has been prescribed to more than 700,000 patients worldwide since its introduction.

Dr Lawrence Blonde of the Ochsner Medical Center in New Orleans said: "This real-world study reinforces the outcomes seen in clinical trials demonstrating better anti-hyperglycaemic efficacy of Victoza when compared to sitagliptin or exenatide."

This comes after Novo Nordisk recently published a study that shed light on the discrimination many diabetes patients suffer as a result of their condition.